)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
CStone Pharmaceuticals (2616) investor relations material
CStone Pharmaceuticals H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary14 Aug, 2025
Executive summary
Revenue for the six months ended June 30, 2025, dropped 80.5% year-over-year to RMB49.4 million, mainly due to lower sales of pralsetinib, price adjustments, and absence of major licensing or milestone deals.
Net loss for the period was RMB270.2 million (Non-IFRS), reversing a prior-year profit, driven by a shift from gross profit to gross loss.
Advanced global expansion with new regulatory approvals and strategic partnerships, notably for sugemalimab in Europe, UK, LATAM, and China.
Four commercialized products with nine approved indications and five territories covered, including major launches in EU and UK.
Sugemalimab became the first PD-L1 developed by a Chinese biopharma to be marketed internationally, with approvals in EU, UK, and China.
Financial highlights
Revenue for 2025 H1 was RMB49.4 million, down from RMB254.2 million year-over-year.
Net loss for 2025 H1 was RMB265.1 million (Non-IFRS), compared to a profit of RMB10.8 million in 2024 H1.
Cash and cash equivalents and time deposits stood at RMB652.8 million as of June 30, 2025, with an additional RMB425.8 million raised in July 2025.
Operating expenses remained stable at RMB179.3 million, with R&D expenses rising 44% year-over-year to RMB105.2 million.
Cost of revenue increased to RMB142.2 million, mainly due to inventory write-downs and early billing for pralsetinib supply.
Outlook and guidance
Anticipates revenue growth in H2 2025 from new licensing agreements, especially Gentili, and potential NRDL inclusion for pralsetinib.
Multiple global regulatory submissions and commercial launches planned for sugemalimab and other pipeline assets.
Focus on advancing CS5001 and CS2009 towards pivotal trials and expanding early-stage candidates.
Ongoing expansion of commercial partnerships in SEA, Australia, Canada, Japan, India, Europe, and LATAM.
Caution that pipeline products may not ultimately be developed or marketed successfully.
Assess impact of pralsetinib NRDL inclusion.
Explain the increase in R&D expenses.
Sugemalimab partnerships beyond Western Europe?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CStone Pharmaceuticals earnings date
H2 202526 Mar, 2026
Next CStone Pharmaceuticals earnings date
H2 202526 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
CStone Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative cancer and autoimmune disease treatments. The company specializes in precision medicine and immuno-oncology therapies, leveraging a pipeline of monoclonal antibodies and targeted small molecules. CStone conducts clinical research and collaborates with global pharmaceutical partners to advance its drug candidates. The company is headquartered in Suzhou, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage